Mangoceuticals, Inc. (NASDAQ: MGRX), operating as MangoRx, announced on October 21, 2024, that it is refuting claims made by Eli Lilly regarding the sale of compounded tirzepatide. Eli Lilly publicly alleged and stated it filed a lawsuit claiming MangoRx improperly copied its weight-loss medicines, Zepbound and Mounjaro.
MangoRx strongly denies all claims made by Eli Lilly concerning the sale of compounded tirzepatide. The company stated its belief in having strong arguments against Eli Lilly's allegations and intends to vigorously defend itself in this legal matter.
MangoRx affirmed its commitment to providing access to safe and efficacious products for patients deemed medically appropriate by U.S. licensed practitioners. The company plans to continue enhancing patient care by offering new solutions while striving to comply with federal, state, and local regulatory guidelines.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.